The rise of the robots

Artificial intelligence is here. But what impact will it have on laboratories? Will it empower pathologists, or lead to a decline in the profession? We look at the issues.

50 years of monitoring quality

To mark the half a century of UK NEQAS, three members of its consortium outline its growth from a short-term, UK-focused project in 1969 to the internationally-recognised organisation it is today.


Reflections of a Quality Manager pt.2

Mairiead MacLennan takes a look at the validation, verification, variation and the uncertainty that surrounds these terms. 


Approaches to lipid therapy

Consultant Chemical Pathologist Professor Tim Reynolds outlines drug developments over recent decades in lipid therapy.


War on cancer pt.2: landmarks in the development of chemotherapy

The second article of two, which briefly reviews the historical developments and use of chemotherapy since 1948 to treat different cancers. 


My Lab: dynamic histopathology service

Trainee Specialist Biomedical Scientist Megan Clarkson gives a guided tour of her laboratory at Salford Royal NHS Foundation Trust.

Romans invasion of the Brit Isles Alarmy

What have the Romans ever done for us?

Apart from the sanitation, the medicine, education, wine, public order, irrigation, roads, the fresh-water system, and public health, what have the Romans ever done for us? Stephen Mortlock investigates.

Top 5 iStock

Top five congress picks

With IBMS Congress 2019 just a few months away and the speakers now confirmed, we ask some of the scientific programme leads which sessions they are looking forward to most and why.

Salt Getty

Recognising pseudohypernatraemia

Biochemistry lead Dan Kelly looks at sodium citrate contamination and how to identify the condition.

Sepsis Science Photo Library

Detecting the silent killer

Rushana Hussain, Clinical Scientist at Royal Bolton Hospital, writes about rapid sepsis detection with MALDI mass spectrometry.

Cancer Screening Getty Images

Cancer screening

With a new report showing that targets for cervical, breast and bowel cancer screening programmes in England have been missed, we explore the limitations and ask what action is needed.